Advertisement

Thrombolysis in Acute Myocardial infarction

      This paper is only available as a PDF. To read, Please Download here.
      This is an extensive review of thrombolysis in myocardial infarction with discussions of the pathophysiology of occlusion, clinical occlusion and rationale for thrombolysis, thrombolytic agents, results of thrombolysis (incidence of reperfusion, left ventricular function, and mortality), complications of thrombolytic therapy, reocclusion, and current recommendations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Cardiology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Adams P.C.
        • Fuster V.
        • Badimon L.
        • et al.
        Platelet vessel wall interactions, rheology and substrate in the acute coronary syndromes. Preventive strategies.
        Am J Cardiol. 1987; 60: 9G-16G
        • AIMS Trial Study Group: Effect of APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial
        Lancet. 1988; 1: 545-549
        • Alderman E.L.
        • Jutzy K.R.
        • Berte L.E.
        • et al.
        Randomized comparison of intravenous versus intracoronary streptokinase for myocardial infarction.
        Am J Cardiol. 1984; 54: 14-19
        • Alexopoulos D.
        • Raine A.E.G.
        • Cobbe S.M.
        Serum sickness complicating intravenous streptokinase therapy in acute myocardial infarction.
        Eur Heart J. 1984; 5: 1010-1012
        • Ambrose J.A.
        • Winters S.L.
        • Arora R.R.
        • et al.
        Coronary angiographic morphology in myocardial infarction: A link between the pathogenesis of unstable angina and myocardial infarction.
        J Am Coll Cardiol. 1985; 6: 1233-1238
        • Ambrose J.A.
        • Winters S.L.
        • Stern A.
        • et al.
        Angiographic morphology and the pathogenesis of unstable angina pectoris.
        J Am Coll Cardiol. 1985; 5: 609-616
        • Ambrosio G.
        • Becker L.C.
        • Hutchins G.M.
        • et al.
        Reduction in experimental infarct size by recombinant human superoxide dismutase: Insights into pathophysiology of reperfusion injury.
        Circulation. 1986; 74: 1424-1433
        • Anderson J.L.
        • Marshall H.W.
        • Bray B.E.
        • et al.
        A ran-domized trial of intracoronary streptokinase in the treatment of acute myocardial infarction.
        N Engl J Med. 1983; 308: 1312-1318
        • Badimon L.
        • Badimon J.J.
        • Galvez A.
        • et al.
        Influence of arterial damage and wall shear rate on platelet deposition: Ex vivo study in a swine model.
        Arteriosclerosis. 1986; 6: 312-320
        • Badimon L.
        • Badimon J.J.
        • Turitto V.T.
        • et al.
        Mechanism of arterial thrombosis: Platelet thrombus deposition in areas of stenosis (abstract).
        Circulation. 1987; 76: IV-102
        • Becker L.C.
        • Ambrosio G.
        Myocardial consequences of reperfusion.
        Prog Cardiovasc Dis. 1987; 30: 23-44
        • Been M.
        • de Bono D.P.
        • Muir A.L.
        • et al.
        Coronary throm-bolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921.
        Br Heart J. 1985; 53: 253-259
        • Bergmann S.R.
        • Fox K.A.A.
        • Ter-Pogossian M.M.
        • et al.
        Clot-selective coronary thrombolysis with tissue-type plasminogen activator.
        Science. 1983; 220: 1181-1183
        • Blumenthal M.R.
        • Wang H.H.
        • Liu L.M.P.
        Experimental coronary arterial occlusion and release: Effects on enzymes, electrocardiograms, myocardial contractility and reactive hyperemia.
        Am J Cardiol. 1975; 36: 225-233
        • Capone R.J.
        • Most A.S.
        Myocardial hemorrhage after coronary reperfusion in pigs.
        Am J Cardiol. 1978; 41: 259-266
        • Cercek B.
        • Lew A.S.
        • Hod H.
        • et al.
        Enhancement of thrombolysis with tissue-type plasminogen activity by pretreatment with heparin.
        Circulation. 1986; 74: 583-587
        • Chandler J.W.
        • Nath H.P.
        • Rogers W.J.
        Heparin and antiplatelet drugs following streptokinase in acute myocardial infarction: What are their effects on vessel patency?.
        J Am Coll Cardiol. 1984; 3: 600
        • Chesebro J.H.
        • Fuster V.
        Antithrombotic therapy for acute myocardial infarction: Mechanisms and prevention of deep venous, left ventricular, and coronary artery thromboembolism.
        Circulation. 1986; 74: 1-10
        • Chesebro J.H.
        • Knatterud G.
        • Roberts R.
        • et al.
        Throm-bolysis In Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase.
        Circulation. 1987; 76: 142-154
      1. Chesebro JH, Penny WJ, Heras M, et al., Which anti-thrombotic therapy has proven most effective for the treatment of deep arterial injury, the ruptured plaque, and post-thrombolysis? In Proceedings of the International Symposium on Limitation of Infarct Size (in press)

        • Collen D.
        On the regulation and control of fibrinolysis: Edward Kowalski Memorial Lecture.
        Thromb Hae-most. 1980; 43: 77-89
        • Collen D.
        Tissue plasminogen activator and its potential in acute myocardial infarction. Presented at the Cardiac Society, Rochester, MNNovember, 1983
        • Collen D.
        Human tissue-type plasminogen activator: From the laboratory to the bedside.
        Circulation. 1985; 72: 18-20
        • Collen D.
        Molecular mechanism of action of newer thrombolytic agents.
        J Am Coll Cardiol. 1987; 10: 11B-15B
        • Collen D.
        • Van de Werf F.
        Coronary arterial throm-bolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
        Am J Cardiol. 1987; 60: 431-434
        • Collen D.
        • Stassen J.M.
        • Stump D.C.
        • et al.
        In vivo synergism of thrombolytic agents.
        Circulation. 1986; 74: 838-842
        • Collen D.
        • Stassen J.M.
        • Verstraete M.
        Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis: Effect of molecular form and dose of activator, age of the thrombus, and route administration.
        J Clin Invest. 1983; 71: 368-376
        • Collen D.
        • Stump D.
        • Van de Werf F.
        • et al.
        Coronary thrombolysis in dogs with intravenously administered human pro-urokinase.
        Circulation. 1985; 72: 384-388
        • Constantini C.
        • Corday E.
        • Lang T.W.
        • et al.
        Revascu-larization after 3 hours of coronary arterial occlusion: Effects on regional cardiac metabolic function and infarct size.
        Am J Cardiol. 1975; 36: 368-384
        • Cortina A.
        • Ambrose J.A.
        • Prieto-Granada J.
        • et al.
        Left ventricular function after myocardial infarction: Clinical and angiographic correlations.
        J Am Coll Cardiol. 1985; 5: 619-624
        • Cowley M.J.
        • Hastillo A.
        • Vetrovec G.W.
        • et al.
        Effects of intracoronary streptokinase in acute myocardial infarction.
        Am Heart J. 1981; 102: 1149-1158
        • Davies M.J.
        The role of the macrophage in human coronary artery thrombosis. Presented at Coronary Artery Disease Conference. San Juan, Puerto RicoFebruary 4, 1988
        • Davies M.J.
        • Thomas A.C.
        Plaque Assuring—the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina.
        Br Heart J. 1985; 53: 363-373
        • DeWood M.A.
        • Spores J.
        • Notske R.
        • et al.
        Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.
        N Engl J Med. 1980; 303: 897-902
        • Eisenberg P.R.
        • Sherman L.
        • Rich M.
        • et al.
        Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis.
        J Am Coll Cardiol. 1986; 75: 1255-1262
        • European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. Streptokinase in acute myocardial infarction
        N Engl J Med. 1979; 301: 797-802
        • Falk E.
        Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi.
        Br Heart J. 1983; 50: 127-134
        • Falk E.
        Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death.
        Circulation. 1985; 71: 699-708
        • Fishbein M.C.
        • Hare C.A.
        • Gissen S.A.
        • et al.
        Identification and quantification of histochemical border zones during the evolution of myocardial infarction in the rat.
        Cardiovasc Res. 1980; 14: 41-49
        • Fishbein M.C.
        • Y-Rit J.
        • Lando U.
        • et al.
        The relationship of vascular injury and myocardial hemorrhage to necrosis after reperfusion.
        Circulation. 1980; 62: 1274-1279
        • Fitzgerald D.J.
        • Catella F.
        • Roy L.
        • et al.
        Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.
        Circulation. 1988; 77: 142-150
        • Fuster V.
        • Steele P.M.
        • Chesebro J.H.
        Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death.
        J Am Coll Cardiol. 1985; 5: 175B-185B
        • Ganz W.
        • Buchbinder N.
        • Marcus H.
        • et al.
        Intracoronary thrombolysis in evolving myocardial infarction.
        Am Heart J. 1981; 101: 4-13
        • Ganz W.
        • Geft I.
        • Shah P.K.
        • et al.
        Intravenous strepto-kinase in evolving acute myocardial infarction.
        Am J Cardiol. 1984; 53: 1209-1216
        • Ganz W.
        • Ninomiya K.
        • Hashida J.
        • et al.
        Intracoronary thrombolysis in acute myocardial infarction: Experimental background and clinical experience.
        Am Heart J. 1981; 102: 1145-1149
        • Gersh B.J.
        • Chesebro J.H.
        • Clements I.P.
        Acute myocardial infarction, B. Management and complications.
        in: Brandenburg R.O. Fuster V. Giuliani E.R. Cardiology: Fundamentals and practice. Year Book Medical, Chicago1987: 1152-1219
        • Gibson R.S.
        • Boden W.E.
        • Theroux P.
        • et al.
        Diltiazem and reinfarction in patients with non-Q-wave myo-cardial infarction. Results of a double-blind, randomized, multicenter trial.
        New Engl J Med. 1986; 315: 423-429
        • Ginks W.R.
        • Sybers H.D.
        • Maroko P.R.
        • et al.
        Coronary artery reperfusion. II. Reduction of myocardial infarct size at 1 week after coronary occlusion.
        J Clin Invest. 1972; 51: 2717-2723
        • GISSI
        Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction.
        Lancet. 1986; 1: 397-402
        • Glazier R.L.
        • Crowell E.B.
        Randomized prospective trial of continuous versus intermittent heparin therapy.
        JAMA. 1976; 236: 1365-1367
        • Gold H.K.
        • Leinbach R.C.
        • Buckley M.J.
        • et al.
        Intracoronary streptokinase in evolving infarction.
        Hosp Pract. 1981; 16: 105-119
        • Graves E.J.
        1983 Summary: National Hospital Discharge Survey. National Center for Health Statistics, Rockville, MDSeptember 18, 1984 (Advance data no. 101)
        • Green J.
        • Harris G.S.
        • Smith R.A.G.
        • et al.
        Acyl-enzymes: A novel class of thrombolytic agents.
        in: Collen D. Lijnen H.R. Verstraete M. Thrombolysis Biological and Therapeutic Properties of New Thrombolytic Agents. Churchill Livingstone, Edinburgh1985: 124-167
        • Guerci A.D.
        • Gerstenblith G.
        • Brinker J.A.
        • et al.
        A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty.
        N Engl J Med. 1987; 317: 1613-1618
        • Gurewich V.
        Experience with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator.
        J Am Coll Cardiol. 1987; 10: 16B-21B
        • Gurewich V.
        • Pannell R.
        Inactivation of single-chain urokinase (pro-urokinase) by thrombin and throm-bin-like enzymes: Relevance of the findings to the interpretation of fibrin binding experiments.
        Blood. 1987; 69: 769-772
        • Hackett D.
        • Davies G.
        • Chierchia S.
        • et al.
        Intermittent coronary occlusion in acute myocardial infarction.
        N Engl J Med. 1987; 317: 1055-1057
        • Hamby R.J.
        • Aintablian A.
        • Schwartz A.
        Reappraisal of the functional significance of the coronary collateral circulation.
        Am J Cardiol. 1976; 38: 305-309
        • Harrison D.G.
        • Ferguson D.W.
        • Collins S.M.
        • et al.
        Re-thrombosis after reperfusion with streptokinase: Importance of geometry of residual lesions.
        Circulation. 1984; 69: 991-999
        • Heras M.
        • Chesebro J.H.
        • Bailey K.
        • et al.
        Dose dependent inhibition by heparin of platelet-thrombus deposition during angioplasty (abstract).
        J Am Coll Cardiol. 1988; 11: 30a
        • Heras M.
        • Chesebro J.H.
        • Penny W.J.
        • et al.
        The importance of adequate heparin dosage in arterial angioplasty (abstract).
        Circulation. 1987; 76: IV-213
        • Hillis L.D.
        • Borer J.
        • Braunwald E.
        • et al.
        High dose intravenous streptokinase for acute myocardial infarction: Preliminary results of a multicenter trial.
        J Am Coll Cardiol. 1985; 6: 957-961
        • Hirsh J.
        • O’Sullivan E.F.
        • Martin M.
        Evaluation of a standard dosage schedule with streptokinase.
        Blood. 1970; 35: 341-349
        • ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM)
        N Engl J Med. 1986; 314: 1465-1471
        • ISIS Collaborative Group. Results of a large randomized trial of intravenous streptokinase and oral aspirin in acute myocardial infarction
        J Am Coll Cardiol. 1988; 11: A1988
        • Jeremy R.W.
        • Hackworthy R.A.
        • Bautovich G.
        • et al.
        Infarct artery perfusion and changes in left ventricular volume in the month after acute mycoardial infarction.
        J Am Coll Cardiol. 1987; 9: 989-995
        • Johnson A.J.
        • McCarty W.R.
        The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase.
        J Clin Invest. 1959; 38: 1627-1643
        • Jolly S.R.
        • Kane W.J.
        • Bailie M.B.
        • et al.
        Canine myocardial reperfusion injury. Its reduction by combined administration of superoxide dismutase and catulase.
        Circ Res. 1984; 54: 277-285
        • Kennedy J.W.
        • Ritchie J.L.
        • Davis K.B.
        • et al.
        Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction.
        N Engl J Med. 1983; 309: 1477-1482
        • Kennedy J.W.
        • Ritchie J.L.
        • Davis K.B.
        • et al.
        The Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction: A 12-month follow-up report.
        N Engl J Med. 1985; 312: 1073-1078
        • Kennedy J.W.
        • Martin G.V.
        • Davis K.B.
        • et al.
        The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomized Trial.
        Circulation. 1988; 77: 345-352
        • Khaja F.
        • Walton Jr, J.A.
        • Brymer J.F.
        • et al.
        Intracoronary fibrinolytic therapy in acute myocardial infarction: Report of a prospective randomized trial.
        N Engl J Med. 1983; 308: 1305-1311
        • Lam J.Y.T.
        • Chesebro J.H.
        • Steele M.
        • et al.
        Deep arterial injury during experimental angioplasty: Relation to a positive indium-Ill-labeled platelet scintigram, quantitative platelet deposition and mural thrombosis.
        J Am Coll Cardiol. 1986; 8: 1380-1386
        • Lam J.Y.T.
        • Chesebro J.H.
        • Steele P.M.
        • et al.
        Is vasospasm related to platelet deposition? In vivo relationship in a pig model of arterial injury.
        Circulation. 1987; 75: 243-248
        • Lam J.Y.T.
        • Chesebro J.H.
        • Heras M.
        • et al.
        Deep and superficial arterial injury: Different affinity for thrombus formation at increaisng shear rate (abstract).
        Circulation. 1987; 76: IV-101
        • Lee G.
        • Amsterdam E.A.
        • Low R.
        • et al.
        Efficacy of percutaneous transluminal coronary recanalization utilizing streptokinase thrombolysis in patients with acute myocardial infarction.
        Am Heart J. 1981; 102: 1159-1167
        • Leiboff R.H.
        • Katz R.J.
        • Wasserman A.G.
        • et al.
        A randomized angiographically controlled trial of intracoronary streptokinase in acute myocardial infarction.
        Am J Cardiol. 1984; 53: 404-407
        • Levin D.C.
        Pathways and functional significance of the coronary collateral circulation.
        Circulation. 1974; 50: 831-837
        • Levin D.C.
        • Fallon J.T.
        Significance of the angiographic morphology of localized coronary stenoses: Histopathologic conditions.
        Circulation. 1982; 66: 316-320
        • Lewis Jr, H.D.
        • Davis J.W.
        • Archibald D.G.
        • et al.
        Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a veterans administration cooperative study.
        N Engl J Med. 1983; 309: 396-403
        • Lijnen H.R.
        • Zamarron C.
        • Blaber M.
        • et al.
        Activation of plasminogen by pro-urokinase. I. Mechanism.
        J Biol Chem. 1986; 261: 1253-1258
        • Mant M.J.
        • O’Brien B.D.
        • Thong K.L.
        • et al.
        Haemorrhagic complications of heparin therapy.
        Lancet. 1977; 1: 1133-1135
        • Marder V.J.
        The use of thrombolytic agents: Choice of patient, drug administration, laboratory monitoring.
        Ann Intern Med. 1979; 90: 802-808
        • Maroko P.R.
        • Libby P.
        • Ginks W.R.
        • et al.
        Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis.
        J Clin Invest. 1972; 51: 2710-2716
        • Mathey D.G.
        • Kuck K.H.
        • Tilsner V.
        • et al.
        Nonsurgical coronary artery recanalization in acute transmural myocardial infarction.
        Circulation. 1981; 63: 489-497
        • Mathey D.G.
        • Sheehan F.H.
        • Schofer J.
        • et al.
        Time from onset of symptoms to thrombolytic therapy: A major determinant of myocardial salvage in patients with acute transmural infarction.
        J Am Coll Cardiol. 1985; 6: 518-525
        • Mathur V.S.
        • Guinn G.A.
        • Burris III, W.H.
        Maximal re-vascularization (reperfusion) in intact conscious dogs after 2 to 5 hours of coronary occlusion.
        Am J Cardiol. 1975; 36: 252-261
        • McNamara J.J.
        • Smith G.T.
        • Suehiro G.T.
        • et al.
        Myocardial viability after transient ischemia in primates.
        J Thorac Cardiovasc Surg. 1974; 68: 248-256
        • Merx W.
        • Dorr R.
        • Rentrop P.
        • et al.
        Evaluation of the effectiveness of intracoronary streptokinase infusion in acute myocardial infarction: Postprocedure management and hospital course in 204 patients.
        Am Heart J. 1981; 102: 1181-1187
        • Mueller H.D.
        • Rao A.K.
        • Forman S.A.
        TIMI Investigators Thrombolysis in myocardial infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.
        J Am Coll Cardiol. 1987; 10: 479-490
        • Naito M.
        • Michelson E.L.
        • Kmetzo J.J.
        • et al.
        Failure of antiarrhythmic drugs to prevent experimental reperfusion ventricular fibrillation.
        Circulation. 1981; 643: 70-79
        • O’Keefe J.H.
        • Chesebro J.H.
        • Bove A.A.
        • et al.
        Prevention of late ventricular dilatation after myocardial infarction by successful thrombolysis (abstract).
        J Am Coll Cardiol. 1987; 9: 61A
        • Ong L.
        • Reiser P.
        • Coromilas J.
        • et al.
        Left ventricular function and rapid release of creatine kinase MB in acute myocardial infarction: Evidence for spontaneous reperfusion.
        N Engl J Med. 1983; 309: 1-6
        • O’Rourke M.
        • Norris R.
        for Sydney/Auckland TICO Group Thrombolysis in Coronary Occlusion (TICO) Group. Improved LV ejection fraction at 21 days following coronary occlusion treated by early intravenous rt-PA infusion (abstract).
        J Am Coll Cardiol. 1988; 11: 105A
        • Pannell R.
        • Gurewich V.
        Pro-urokinase: A study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.
        Blood. 1986; 67: 1215-1223
        • Puri P.S.
        Contractile and biochemical effects of coronary reperfusion after extended periods of coronary occlusion.
        Am J Cardiol. 1975; 36: 244-251
        • Rao A.K.
        • Pratt C.
        • Berke A.
        • et al.
        Thrombolysis in Myo-cardial Infarction (TIMI) Trial-Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
        J Am Coll Cardiol. 1988; 11: 1-11
        • Reduto L.A.
        • Freund G.C.
        • Gaeta J.M.
        • et al.
        Coronary artery reperfusion in acute myocardial infarction: Beneficial effects of intracoronary streptokinase of left ventricular salvage and performance.
        Am Heart J. 1981; 102: 1168-1177
        • Reimer K.A.
        • Lowe J.E.
        • Rasmussen M.M.
        • et al.
        The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size versus duration of coronary occlusion in dogs.
        Circulation. 1977; 56: 786-794
        • Rentrop K.P.
        Thrombolytic therapy in patients with acute myocardial infarction.
        Circulation. 1985; 71: 627-631
        • Rentrop P.
        • Blanke H.
        • Karsch K.R.
        • et al.
        Changes in left ventricular function after intracoronary streptokinase infusion in clinically evolving myocardial infarction.
        Am Heart J. 1981; 102: 1188-1193
        • Ritchie J.L.
        • Davis K.B.
        • Williams D.L.
        • et al.
        Global and regional left ventricular function and tomographic radionuclide perfusion: The Western Washington Intracoronary Streptokinase Trial in Myocardial Infarction.
        Circulation. 1984; 70: 867-875
        • Rogers W.J.
        • Hood Jr, W.P.
        • Mantle J.A.
        • et al.
        Return of left ventricular function after reperfusion in patients with myocardial infarction: Importance of subtotal stenoses or intact collaterals.
        Circulation. 1984; 69: 338-349
        • Rogers W.J.
        • Mantle J.A.
        • Hood Jr, W.P.
        • et al.
        Prospective randomized trial of intravenous and intracoronary stretokinase in acute myocardial infarction.
        Circulation. 1983; 68: 1051-1061
        • Rovelli F.
        • De Vita C.
        • Feruglio A.
        • et al.
        GISSI Trial: Early results and late follow-up.
        J Am Coll Cardiol. 1987; 10: 33B-39B
        • Saltups A.
        • Boxall J.
        • Ho B.
        • et al.
        Intracoronary versus intravenous streptokinase in myocardial infarction.
        J Am Coll Cardiol. 1984; 3: 525
        • Salzman E.W.
        • Deykin D.
        • Shapiro R.M.
        • et al.
        Management of heparin therapy. Controlled prospective trial.
        N Engl J Med. 1975; 292: 1046-1050
        • Schaper W.
        • Schaper J.
        Der experimentelle infarkt.
        Verh Dtsch Ges Herz Kreislaufforsch. 1979; 45: 1-6
        • Schroder R.
        • Biamino G.
        • von Leitner E.R.
        • et al.
        Intravenous short-term infusion of streptokinase in acute myocardial infarction.
        Circulation. 1983; 67: 536-548
        • Schroder R.
        • Neuhaus K.L.
        • Leizorovicz A.
        • et al.
        A prospective placebo-controlled double-blind multi-center trial of intravenous streptokinase in acute myocardial infarction (ISAM): Long-term mortality and morbidity.
        J Am Coll Cardiol. 1987; 9: 197-203
        • Sheehan F.H.
        • Braunwald E.
        • Canner P.
        • et al.
        The effect of intravenous thrombolytic therapy on left ventricular function: A report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase) Trial.
        Circulation. 1987; 75: 817-829
        • Simoons M.L.
        • Serruys P.W.
        • Van den Brand M.
        • et al.
        Improved survival after early thrombolysis in acute myocardial infarction: A randomized trial by the Interuniversity Cardiology Institute in The Netherlands.
        Lancet. 1985; 2: 578-581
        • Spann J.F.
        • Sherry S.
        • Carabello B.A.
        • et al.
        Coronary thrombolysis by intravenous streptokinase in acute myocardial infarction: Acute and follow-up studies.
        Am J Cardiol. 1984; 53: 655-661
        • Stack R.S.
        • O’Connor C.M.
        • Mark D.M.
        • et al.
        Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous streptokinase.
        Circulation. 1988; 77: 151-161
        • Steen T.A.
        • Tinker J.H.
        • Tarhan S.
        Myocardial reinfarction after anesthesia and surgery.
        JAMA. 1978; 239: 2566-2570
        • Steele P.M.
        • Chesebro J.H.
        • Stanson A.W.
        • et al.
        Balloon angioplasty: Natural history of the pathophysiological response to injury in a pig model.
        Circ Res. 1985; 57: 105-112
        • Tillett W.S.
        • Garner R.L.
        The fibrinolytic activity of hemolytic streptococci.
        J Exp Med. 1933; 58: 485-502
      2. TIMI Research Group The comparison of immediate catheterization versus delayed catheterization to perform angioplasty following thrombolytic therapy (TIMI IIA). Presented at American Heart Association Meeting, Anaheim, CA, November 1987

        • Topol E.J.
        • Califf R.M.
        • George B.S.
        • et al.
        A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.
        N Engl J Med. 1987; 317: 518-588
        • Turpie A.G.G.
        • Robinson J.
        • Mulji A.S.
        • et al.
        Prevention of left ventricular mural thrombosis in acute myocardial infarction: A double-blind trial comparing high dose with low dose subcutaneous calcium heparin (abstract).
        J Am Coll Cardiol. 1988; 11: A1988
        • Van de Werf F.
        • Nobuhara M.
        • Collen D.
        Coronary thrombolysis with human single chain urokinase-type plasminogen activator (scu-PA) in patients with acute myocardial infarction.
        Ann Intern Med. 1986; 104: 345-348
        • Van de Werf F.
        • Van Haecke J.
        • De Geest H.
        • et al.
        Coronary thrombolysis with recombinant single chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
        Circulation. 1986; 74: 1066-1070
        • Verstraete M.
        • Bernard R.
        • Bory M.
        • et al.
        Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.
        Lancet. 1985; 1: 842-847
        • Verstraete M.
        • Vermylen J.
        • Amery A.
        • et al.
        Throm-bolytic therapy with streptokinase using a standard dosage scheme.
        Br Med J. 1966; 1: 454-456
        • Weimar W.
        • Stibbe J.
        • van Seyen A.J.
        Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator.
        Lancet. 1981; 2: 1018-1020
        • White H.D.
        • Norris R.M.
        • Brown M.A.
        • et al.
        Left ventricular and systolic volume as the major determinant of survival after recovery from myocardial infarction.
        Circulation. 1987; 76: 44-51
        • White H.D.
        • Norris R.M.
        • Brown M.A.
        • et al.
        Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction.
        N Engl J Med. 1987; 317: 850-855